Jundishapur Journal of Natural Pharmaceutical Products

Published by: Kowsar

Optimization of Vasopressin Type 2 Receptor Expression in Escherichia coli BL21

Fatemeh Moazen 1 , Peyman Eshaghi Djabali 1 , Naemeh Parsapour 1 , Fatemeh Mohamadzadeh 1 , Abbas Jafarian Dehkordi 1 and Hamid Mir Mohammad Sadeghi 1 , *
Authors Information
1 Department of Pharmaceutical Biotechnology, Isfahan Pharmaceutical Science Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Science, Isfahan, IR Iran
Article information
  • Jundishapur Journal of Natural Pharmaceutical Products: February 01, 2016, 11 (1); e25441
  • Published Online: February 20, 2016
  • Article Type: Research Article
  • Received: November 18, 2014
  • Revised: May 21, 2015
  • Accepted: June 10, 2015
  • DOI: 10.17795/jjnpp-25441

To Cite: Moazen F, Eshaghi Djabali P, Parsapour N, Mohamadzadeh F, Jafarian Dehkordi A, et al. Optimization of Vasopressin Type 2 Receptor Expression in Escherichia coli BL21, Jundishapur J Nat Pharm Prod. 2016 ; 11(1):e25441. doi: 10.17795/jjnpp-25441.

Copyright © 2016, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Zhang R, Xie X. Tools for GPCR drug discovery. Acta Pharmacol Sin. 2012; 33(3): 372-84[DOI][PubMed]
  • 2. Barberis C, Mouillac B, Durroux T. Structural bases of vasopressin/oxytocin receptor function. J Endocrinol. 1998; 156(2): 223-9[PubMed]
  • 3. Calmont A, Reichwald K, Ronco P, Rossert J. Identification of a short cis-acting element in the human vasopressin type 2 receptor gene which confers high-level expression of a reporter gene specifically in collecting duct cells. Mol Endocrinol. 2000; 14(10): 1682-95[DOI][PubMed]
  • 4. Ferguson JW, Therapondos G, Newby DE, Hayes PC. Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis. Clin Sci (Lond). 2003; 105(1): 1-8[DOI][PubMed]
  • 5. Mouillac B, Chini B, Balestre MN, Elands J, Trumpp-Kallmeyer S, Hoflack J, et al. The binding site of neuropeptide vasopressin V1a receptor. Evidence for a major localization within transmembrane regions. J Biol Chem. 1995; 270(43): 25771-7[PubMed]
  • 6. Birnbaumer M. Vasopressin Receptor Mutations and Nephrogenic Diabetes Insipidus. Arch Med Res. 1999; 30(6): 465-74[DOI]
  • 7. Schulein R, Rutz C, Rosenthal W. Membrane targeting and determination of transmembrane topology of the human vasopressin V2 receptor. J Biol Chem. 1996; 271(46): 28844-52[PubMed]
  • 8. Morooka H, Iwanaga Y, Tamaki Y, Takase T, Akahoshi Y, Nakano Y, et al. Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure. Circ Heart Fail. 2012; 5(4): 484-92[DOI][PubMed]
  • 9. Birnbaumer M. Mutations and diseases of G protein coupled receptors. J Recept Signal Transduct Res. 1995; 15(1-4): 131-60[DOI][PubMed]
  • 10. Sadeghi HM, Innamorati G, Birnbaumer M. An X-linked NDI mutation reveals a requirement for cell surface V2R expression. Mol Endocrinol. 1997; 11(6): 706-13[DOI][PubMed]
  • 11. Sambrook J, Russell David W. Molecular cloning: a laboratory manual. Vol. 3. 1989;
  • 12. Dormiani K, Khazaie Y, Sadeghi HM, Rabbani M, Moazen F. Cloning and expression of a human tissue plasminogen activator variant: K2S in Escherichia coli. Pak J Biol Sci. 2007; 10(6): 946-9[PubMed]
  • 13. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227(5259): 680-5[PubMed]
  • 14. Shafiee F, Moazen F, Rabbani M, Mir Mohammad Sadeghi H. Optimization of the Expression of Reteplase in Escherichia coli TOP10 Using Arabinose Promoter. Jundishapur J Nat Pharm Prod. 2015; 10(1)
  • 15. Studier FW, Moffatt BA. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J Mol Biol. 1986; 189(1): 113-30
  • 16. Hochuli E. Purification of recombinant proteins with metal chelate adsorbent. Genet Eng (N Y). 1990; 12: 87-98[PubMed]
  • 17. Grabski A, Mehler M, Drott D. The Overnight Express Autoinduction System: High-density cell growth and protein expression while you sleep. Nat Methods. 2005; 2(3): 233-5[DOI]
  • 18. Schein CH. Production of Soluble Recombinant Proteins in Bacteria. Nat Biotechnol. 1989; 7(11): 1141-9[DOI]
  • 19. Akbari V, Mir Mohammad Sadeghi H, Jafrian-Dehkordi A, Abedi D, Chou CP. Functional expression of a single-chain antibody fragment against human epidermal growth factor receptor 2 (HER2) in Escherichia coli. J Ind Microbiol Biotechnol. 2014; 41(6): 947-56[DOI][PubMed]
  • 20. Gholipour A, Moosavian M, Galehdari H, Makvandi M, Memari H, Alvandi A. Cloning and periplasmic expression of peptidoglycan-associated lipoprotein (PAL) protein of Legionella pneumophila in Escherichia coli. Jundishapur J Microbiol. 2010; 3(1): 1-9
  • 21. Khalesi R, Ehsaei Z, Mansouri M, Amani J, Salimian J. Optimization of gene expression and purification of enterotoxigenic Escherichia coli recombinant LTB protein and antibody production against it. Kowsar Med J. 2010; 15(3): 141-7
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments